Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review
Globally, lung cancer is the leading cause of cancer-related death. The majority of non-small cell lung cancer (NSCLC) tumours express epidermal growth factor receptor (EGFR), which allows for precise and targeted therapy in these patients. The dysregulation of EGFR in solid epithelial cancers has t...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/5/1206 |
| _version_ | 1827692470590242816 |
|---|---|
| author | Emma-Anne Karlsen Sam Kahler Joan Tefay Shannon R. Joseph Fiona Simpson |
| author_facet | Emma-Anne Karlsen Sam Kahler Joan Tefay Shannon R. Joseph Fiona Simpson |
| author_sort | Emma-Anne Karlsen |
| collection | DOAJ |
| description | Globally, lung cancer is the leading cause of cancer-related death. The majority of non-small cell lung cancer (NSCLC) tumours express epidermal growth factor receptor (EGFR), which allows for precise and targeted therapy in these patients. The dysregulation of EGFR in solid epithelial cancers has two distinct mechanisms: either a kinase-activating mutation in EGFR (EGFR-mutant) and/or an overexpression of wild-type EGFR (wt-EGFR). The underlying mechanism of EGFR dysregulation influences the efficacy of anti-EGFR therapy as well as the nature of resistance patterns and secondary mutations. This review will critically analyse the mechanisms of EGFR expression in NSCLC, its relevance to currently approved targeted treatment options, and the complex nature of secondary mutations and intrinsic and acquired resistance patterns in NSCLC. |
| first_indexed | 2024-03-10T11:24:35Z |
| format | Article |
| id | doaj.art-1db3a939e3434069846b4f010dceeaf6 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T11:24:35Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-1db3a939e3434069846b4f010dceeaf62023-11-21T19:46:31ZengMDPI AGCells2073-44092021-05-01105120610.3390/cells10051206Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A ReviewEmma-Anne Karlsen0Sam Kahler1Joan Tefay2Shannon R. Joseph3Fiona Simpson4Simpson Laboratory, The University of Queensland Diamantina Institute, Woolloongabba, Brisbane 4102, AustraliaFaculty of Medicine, The University of Queensland, St Lucia 4067, AustraliaFaculty of Medicine, The University of Queensland, St Lucia 4067, AustraliaSimpson Laboratory, The University of Queensland Diamantina Institute, Woolloongabba, Brisbane 4102, AustraliaSimpson Laboratory, The University of Queensland Diamantina Institute, Woolloongabba, Brisbane 4102, AustraliaGlobally, lung cancer is the leading cause of cancer-related death. The majority of non-small cell lung cancer (NSCLC) tumours express epidermal growth factor receptor (EGFR), which allows for precise and targeted therapy in these patients. The dysregulation of EGFR in solid epithelial cancers has two distinct mechanisms: either a kinase-activating mutation in EGFR (EGFR-mutant) and/or an overexpression of wild-type EGFR (wt-EGFR). The underlying mechanism of EGFR dysregulation influences the efficacy of anti-EGFR therapy as well as the nature of resistance patterns and secondary mutations. This review will critically analyse the mechanisms of EGFR expression in NSCLC, its relevance to currently approved targeted treatment options, and the complex nature of secondary mutations and intrinsic and acquired resistance patterns in NSCLC.https://www.mdpi.com/2073-4409/10/5/1206epidermal growth factor receptornon-small cell lung cancerdrug resistancetyrosine kinase inhibitormonoclonal antibody |
| spellingShingle | Emma-Anne Karlsen Sam Kahler Joan Tefay Shannon R. Joseph Fiona Simpson Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review Cells epidermal growth factor receptor non-small cell lung cancer drug resistance tyrosine kinase inhibitor monoclonal antibody |
| title | Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review |
| title_full | Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review |
| title_fullStr | Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review |
| title_full_unstemmed | Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review |
| title_short | Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review |
| title_sort | epidermal growth factor receptor expression and resistance patterns to targeted therapy in non small cell lung cancer a review |
| topic | epidermal growth factor receptor non-small cell lung cancer drug resistance tyrosine kinase inhibitor monoclonal antibody |
| url | https://www.mdpi.com/2073-4409/10/5/1206 |
| work_keys_str_mv | AT emmaannekarlsen epidermalgrowthfactorreceptorexpressionandresistancepatternstotargetedtherapyinnonsmallcelllungcancerareview AT samkahler epidermalgrowthfactorreceptorexpressionandresistancepatternstotargetedtherapyinnonsmallcelllungcancerareview AT joantefay epidermalgrowthfactorreceptorexpressionandresistancepatternstotargetedtherapyinnonsmallcelllungcancerareview AT shannonrjoseph epidermalgrowthfactorreceptorexpressionandresistancepatternstotargetedtherapyinnonsmallcelllungcancerareview AT fionasimpson epidermalgrowthfactorreceptorexpressionandresistancepatternstotargetedtherapyinnonsmallcelllungcancerareview |